Recent share performance and business snapshot

QuidelOrtho (QDEL) has drawn investor attention after a mixed stretch for the stock, with a gain of about 31% over the past month but a decline of roughly 31% over the past 3 months.

The company has a market value of about US$1.0b and last closed at US$14.33. It focuses on diagnostic testing solutions through four segments: Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics.

QuidelOrtho reports annual revenue of US$2,657.2m and a net loss of US$1,210.9m, with revenue growth of 3.5% and net income growth of just over 10x on the latest annual figures provided.

While QuidelOrtho’s 1 month share price return of 30.75% suggests short term momentum is building from a low base, longer term total shareholder returns over 3 and 5 years remain deeply negative. This highlights ongoing market caution around the business.

If you are weighing QuidelOrtho’s recent rebound against other opportunities in healthcare-related technologies, this could be a good moment to hunt for diagnostic and treatment-focused AI stocks using the 39 healthcare AI stocks

With the stock rebounding over the past month yet still carrying a loss over 1 and 3 years, and trading below some analyst targets and an intrinsic estimate, is this a reset that creates opportunity, or is the market already pricing in future growth?

Most Popular Narrative: 58.7% Undervalued

QuidelOrtho's most followed narrative pegs fair value at about $34.67 per share versus the last close at $14.33, framing a wide gap that hinges on future earnings power and margin recovery.

Acquisition of LEX Diagnostics and the planned commercialization of its rapid molecular point-of-care platform addresses the trend toward fast, decentralized testing and is likely to increase recurring revenues and enhance margins as high-value, high-velocity diagnostic solutions become more prevalent.

Analysts are focusing on steady revenue expansion, a swing in profit margins from deep losses toward industry norms, and a future earnings multiple below many medical equipment peers. Curious which assumptions carry the most weight in that $34.67 figure and how they tie into QuidelOrtho's shift toward higher value testing platforms and international growth ambitions? The full narrative breaks down the chain of estimates that connect today's loss-making profile to that fair value target.

Result: Fair Value of $34.67 (UNDERVALUED)

However, there are still clear swing factors, including post pandemic COVID testing weakness and product discontinuations, that could limit the earnings recovery this narrative leans on.

Next Steps

Mixed messages on value and risk so far? Take a moment to weigh both sides for yourself by starting with the 2 key rewards and 3 important warning signs.

Looking for more investment ideas?

If QuidelOrtho has you thinking differently about risk and reward, do not stop here. Broaden your watchlist now or you may overlook something important.

• Target potential mispricings by scanning 49 high quality undervalued stocks that combine solid fundamentals with market pessimism that might be too harsh.
• Strengthen your income focus by checking 9 dividend fortresses that pair higher yields with an emphasis on resilience.
• Prioritize sturdier balance sheets by reviewing the solid balance sheet and fundamentals stocks screener (46 results) and see which companies keep financial risk in tighter check.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.